Here's why the Cynata (ASX:CYP) share price is rising today

This biotechnology company has signed an agreement.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Cynata Therapeutics Limited (ASX: CYP) share price is in the green today following news of a company deal.

Shares in the biotechnology company are up 4.1%, trading at 50 cents at the time of writing.

Let's look at what might be impacting the Cynata share price today.

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.

Image source: Getty Images

What did the company announce?

Cynata advised it was entering a manufacturing services agreement with the Wisconsin-based Fujifilm Cellular Dynamics (FCDI).

The agreement will enable FCDI to manufacture stem cell technology for Cynata to use in clinical trials and potential commercialisation. These stem cells are derived from induced pluripotent stem cells.

Cynata is an Australian-based company that is developing therapies to treat human disease using its Cymerus therapeutic stem cell technology. This includes its lead product CYP-001, which is at the planning stage for a phase 2 clinical trial.

FCDI is a global developer of human-induced pluripotent stem cell technologies.

What did management say?

Commenting on the agreement, Cynata chief operating officer Dr Killian Kelly said:

Ultimately, we foresee FCDI manufacturing product for our growing pipeline of clinical trials in high value indications and potentially for commercial use.

This provides a turn-key manufacturing solution that our future corporate partners may avail themselves of.

Importantly, FCDI has also confirmed a strong commitment to our relationship by agreeing to extending the voluntary escrow over their shares in Cynata.

Cynata initially flagged the deal to the market in September.

Now the deal is sealed, the companies will set up a manufacturing process for the Cymerus stem cell technology at the FCDI's US base.

Cynata share price snapshot

The Cynata share price has plummeted this year, down nearly 28% since January.

In contrast, the S&P/ASX 200 Index (ASX: XJO) is returning nearly 12% this year to date.

The company's shares have lifted more than 11% in the past five days alone.

The company has a market capitalisation of around $71 million based on the current share price.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Two happy pharmacists standing together in a pharmacy.
Healthcare Shares

Why Clarity Pharmaceuticals shares just fell 5% on today's announcement

Investors are balancing Clarity's long-term potential against near-term uncertainty.

Read more »

Medical workers examine an xray or scan in a hospital laboratory.
Healthcare Shares

Still down 40%, are Pro Medicus shares primed to break out?

Two major US contract wins in as many weeks could mark a turning point in sentiment.

Read more »

Happy healthcare workers in a lab.
Healthcare Shares

Telix share price leaping higher today on $3 billion US news

Investors are snapping up Telix shares on Monday following big US news.

Read more »

Four smiling young medics with arms crossed stand outside a hospital.
Healthcare Shares

Pro Medicus locks in 5-year, $37m Northwestern Medicine contract renewal

Pro Medicus has renewed its major contract with Northwestern Medicine, locking in higher fees and strengthened client ties for the…

Read more »

Rising healthcare ASX share price represented by doctor giving thumbs up
Healthcare Shares

Telix Pharmaceuticals announces US$40m Regeneron radiopharma deal

Telix Pharmaceuticals has announced a US$40m strategic collaboration with Regeneron for innovative radiopharmaceutical cancer therapies.

Read more »

Two health workers taking a break.
Healthcare Shares

It could be time to buy-low on this ASX small-cap stock according to brokers

This ASX healthcare stock keeps attracting positive ratings, with one broker now tipping a 268% rise.

Read more »

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

Broker sees 26% upside in ASX healthcare share behind Chemist Warehouse

Morgans has just upgraded its rating on this ASX healthcare stock due to ongoing share price weakness.

Read more »

Woman using a pen on a digital stock market chart in an office.
Healthcare Shares

Why this ASX healthcare stock is surging while the market sinks on Middle East fears

Avita shares surge as a US government contract boosts sentiment again

Read more »